Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW INDICATIONS

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

JHOP - October 2021 Vol 11, No 5 - FDA Updates
Download PDF

On August 19, 2021, the FDA accelerated the approval of nivolumab (Opdivo; Bristol Myers Squibb) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk for recurrence after undergoing radical resection. This is the first FDA approval of any immunotherapy for adjuvant treatment of patients with high-risk urothelial carcinoma.

This approval also converted the accelerated approval of nivolumab for advanced or metastatic urothelial carcinoma to a regular approval. Nivolumab has previously been approved for many indications.

This new approval was based on the CheckMate-274 study, a randomized, double-blind, placebo-controlled clinical trial of patients who were within 120 days of radical resection of urothelial carcinoma of the bladder or upper urinary tract and were at high risk for recurrence. Patients were randomized in a 1:1 ratio to nivolumab 240 mg or to placebo every 2 weeks until recurrence or unacceptable toxicity, for a maximum of 1 year.

The primary end point was disease-free survival (DFS) in the intent-to-treat (ITT) population and in patients with PD-L1 expression ≥1%. A prespecified interim analysis showed a significant improvement in DFS in the nivolumab arm versus placebo. In the ITT analysis, the median DFS was 20.8 months with nivolumab versus 10.8 months with placebo (P = .0008). For patients with PD-L1 ≥1%, the median DFS was not reached in the nivolumab arm versus 8.4 months in the placebo arm (P = .0005). The overall survival data are immature, with 33% of deaths reported in the overall study population.

The most common (≥20%) adverse events with nivolumab in the CheckMate-274 study were rash, fatigue, diarrhea, pruritus, musculoskeletal pain, and urinary tract infection.

Related Items
Cytalux, a Novel Imaging Agent, FDA Approved for Diagnosing Inoperable Ovarian Cancer Lesions
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination FDA Approved for Multiple Myeloma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Updates
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.